SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    0 In recent years there has been a dramatic increase in the abuse of and dependency on prescription opioid pain medications ( also known as narcotics ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    0 In_II recent_JJ years_NNT2 there_EX_RL has_VHZ been_VBN a_AT1 dramatic_JJ increase_NN1 in_II the_AT abuse_NN1 of_IO and_CC dependency_NN1 on_II prescription_NN1 opioid_NN1_JJ pain_NN1 medications_NN2 (_Y also_RR known_VVN as_II narcotics_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    1 Viewed as safer than street drugs like heroin , prescription pain pill misuse is on the increase in all age ranges .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    1 Viewed_VVN_VVD as_CSA_RG@_II@ safer_JJR_RRR than_CSN street_NN1 drugs_NN2 like_II heroin_NN1 ,_Y prescription_NN1 pain_NN1 pill_NN1 misuse_NN1 is_VBZ on_II the_AT increase_NN1 in_II all_DB age_NN1_VV0@ ranges_NN2_VVZ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    2 Frequently abused prescription pain medications include hydrocodone ( Lorcet , Lortab , Vicodin ) , oxycodone ( OxyContin , Percocet , Percodan ) , codeine ( Tylenol 2s , 3s , and 4s ) , fentanyl ( Duragesic ) , and morphine ( MS Contin ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    2 Frequently_RR abused_VVN_JJ@ prescription_NN1 pain_NN1 medications_NN2 include_VV0 hydrocodone_NN1 (_Y Lorcet_NP1_VV0_NN1 ,_Y Lortab_NP1 ,_Y Vicodin_NP1 )_Y ,_Y oxycodone_NN1_VV0 (_Y OxyContin_NP1 ,_Y Percocet_NP1_VV0_NN1 ,_Y Percodan_NP1 )_Y ,_Y codeine_NN1 (_Y Tylenol_NP1 2s_MC2 ,_Y 3s_MC2 ,_Y and_CC 4s_MC2 )_Y ,_Y fentanyl_NN1 (_Y Duragesic_NN1_JJ )_Y ,_Y and_CC morphine_NN1 (_Y MS_NNB Contin_NP1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    3 These drugs are commonly prescribed for acute pain ( for example , tooth , post-injury , or surgery pain ) or chronic pain ( for example , back pain or pain associated with malignancy ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    3 These_DD2 drugs_NN2 are_VBR commonly_RR prescribed_VVN for_IF acute_JJ pain_NN1 (_Y for_REX21 example_REX22 ,_Y tooth_NN1 ,_Y post-injury_NN1_JJ ,_Y or_CC surgery_NN1 pain_NN1 )_Y or_CC chronic_JJ pain_NN1 (_Y for_REX21 example_REX22 ,_Y back_NN1_JJ@ pain_NN1 or_CC pain_NN1 associated_VVN with_IW malignancy_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    4 Methadone , which is used both for the treatment of opioid dependence and for pain , is rising as a primary drug of abuse as well ( Maxwell , 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    4 Methadone_VV0_NN1_NP1@ ,_Y which_DDQ is_VBZ used_VVN both_RR for_IF the_AT treatment_NN1 of_IO opioid_JJ_NN1 dependence_NN1 and_CC for_IF pain_NN1 ,_Y is_VBZ rising_VVG as_II a_AT1 primary_JJ_NN1 drug_NN1 of_IO abuse_NN1 as_RR21_RG well_RR22_RR (_Y Maxwell_NP1 ,_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    5 <p> Statistics over the past five years have shown that the misuse of prescription pain medications by students in grades 8 through 12 continues , alcohol , and steroids has decreased .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    5 <p>_Y Statistics_NN over_II the_AT past_JJ five_MC years_NNT2 have_VH0 shown_VVN that_CST the_AT misuse_NN1 of_IO prescription_NN1 pain_NN1 medications_NN2 by_II students_NN2 in_II grades_NN2 8_MC through_II 12_MC continues_VVZ ,_Y alcohol_NN1 ,_Y and_CC steroids_NN2 has_VHZ decreased_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    6 Data from admissions to treatment facilities show that heroin as a primary drug of choice decreased from 2000 to 2005 ; during that same time period , admissions for other opioids increased ( Center for Substance Abuse Research , 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    6 Data_NN from_II admissions_NN2 to_II treatment_NN1 facilities_NN2 show_VV0 that_DD1_CST heroin_NN1 as_II_CSA a_AT1 primary_JJ_NN1 drug_NN1 of_IO choice_NN1 decreased_VVN_VVD from_II 2000_MC to_II 2005_MC ;_Y during_II that_DD1 same_DA time_NNT1 period_NN1 ,_Y admissions_NN2 for_IF other_JJ opioids_NN2 increased_VVN_VVD (_Y Center_NN1 for_IF Substance_NN1 Abuse_NN1 Research_NN1 ,_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    7 According to the National Survey on Drug Use and Health ( NSDUH ) report ( NSDUH , 2006 ) , nonmedical use of prescription pain medications has increased among young adults ages 18 to 25 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    7 According_II21 to_II22 the_AT National_JJ Survey_NN1 on_II Drug_NN1 Use_NN1 and_CC Health_NN1 (_Y NSDUH_NP1 )_Y report_NN1 (_Y NSDUH_NP1_NN1 ,_Y 2006_MC )_Y ,_Y nonmedical_JJ use_NN1 of_IO prescription_NN1 pain_NN1 medications_NN2 has_VHZ increased_VVN among_II young_JJ adults_NN2 ages_VVZ@_NN2 18_MC to_II 25_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    8 More people initiated use of prescription pain relievers in 2004 than began using marijuana or cocaine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    8 More_DAR people_NN initiated_VVD_JJ@_VVN use_NN1 of_IO prescription_NN1 pain_NN1 relievers_VVZ in_II 2004_MC than_CSN began_VVD using_VVG marijuana_NN1 or_CC cocaine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0    9 Often these drugs are relatively easy to obtain , are viewed as safer than illegal drugs , and are less shameful to use .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0    9 Often_RR these_DD2 drugs_NN2 are_VBR relatively_RR easy_JJ to_TO obtain_VVI ,_Y are_VBR viewed_VVN as_CSA_II@_RG@ safer_JJR_RRR than_CSN illegal_JJ drugs_NN2 ,_Y and_CC are_VBR less_RGR shameful_JJ to_TO use_VVI ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   10 Although prescription pain pills are from the same class of drugs as heroin , the difficulty of diagnosis of abuse and dependence on them is increased because of their legitimate use and surrounding misconceptions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   10 Although_CS prescription_NN1 pain_NN1 pills_NN2 are_VBR from_II the_AT same_DA class_NN1 of_IO drugs_NN2 as_CSA heroin_NN1 ,_Y the_AT difficulty_NN1 of_IO diagnosis_NN1 of_IO abuse_NN1 and_CC dependence_NN1 on_II them_PPHO2 is_VBZ increased_VVN because_II21 of_II22 their_APPGE legitimate_JJ use_NN1 and_CC surrounding_JJ_VVG misconceptions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   11 <p> National Center of Health Statistics ( Maxwell , 2006 ) data indicated that narcotic analgesics such as hydrocodone , oxycodone , and methadone were more likely to be or cocaine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   11 <p>_Y National_JJ Center_NN1 of_IO Health_NN1 Statistics_NN (_Y Maxwell_NP1 ,_Y 2006_MC )_Y data_NN indicated_VVD_VVN that_DD1_CST narcotic_NN1 analgesics_NN2 such_II21 as_II22 hydrocodone_NN1 ,_Y oxycodone_VV0_NN1 ,_Y and_CC methadone_NN1 were_VBDR more_RGR likely_JJ to_TO be_VBI or_CC cocaine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   12 The 213 percent increase in methadone accidental poisoning deaths between 1999 and 2003 was associated with the use of methadone as a pain medication rather than in opioid treatment programs ( Maxwell , 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   12 The_AT 213_MC percent_NNU increase_NN1_VV0 in_II methadone_NN1 accidental_JJ poisoning_NN1 deaths_NN2 between_II 1999_MC and_CC 2003_MC was_VBDZ associated_VVN with_IW the_AT use_NN1 of_IO methadone_NN1 as_II_CSA a_AT1 pain_NN1 medication_NN1 rather_II21_CS21@ than_II22_CS22@ in_II opioid_JJ_NN1 treatment_NN1 programs_NN2 (_Y Maxwell_NP1 ,_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   13 Such alarming statistics about the increase in the prevalence of prescription pain medication misuse with the corresponding damage to individuals and to society calls for study and better services .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   13 Such_DA alarming_JJ statistics_NN about_II the_AT increase_NN1 in_II the_AT prevalence_NN1 of_IO prescription_NN1 pain_NN1 medication_NN1 misuse_NN1 with_IW the_AT corresponding_JJ damage_NN1 to_II individuals_NN2 and_CC to_II society_NN1 calls_VVZ_NN2 for_IF study_NN1 and_CC better_JJR services_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   14 <p> Individuals who abuse pain medication present a unique population in their sociodemographic characteristics and drug use patterns .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   14 <p>_Y Individuals_NN2 who_PNQS abuse_VV0@ pain_NN1 medication_NN1 present_NN1_VV0@ a_AT1 unique_JJ population_NN1 in_II their_APPGE sociodemographic_JJ characteristics_NN2 and_CC drug_NN1 use_NN1_VV0 patterns_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   15 More than half of the new users of prescription pain relievers are female , the average age of first nonmedical use of pain relievers was 25 , and almost 90 percent of new users are white ( NSDUH , 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   15 More_DAR than_CSN half_DB of_IO the_AT new_JJ users_NN2 of_IO prescription_NN1 pain_NN1 relievers_VVZ are_VBR female_JJ ,_Y the_AT average_JJ_NN1 age_NN1 of_IO first_MD nonmedical_JJ use_NN1 of_IO pain_NN1 relievers_VVZ was_VBDZ 25_MC ,_Y and_CC almost_RR 90_MC percent_NNU of_IO new_JJ users_NN2 are_VBR white_JJ (_Y NSDUH_NP1_NN1 ,_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   16 This increase in the abuse of opioids by this group raises the need to target this population for treatment and to examine the effectiveness of existing treatment modalities .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   16 This_DD1 increase_NN1 in_II the_AT abuse_NN1 of_IO opioids_NN2 by_II this_DD1 group_NN1 raises_VVZ the_AT need_NN1 to_TO target_VVI this_DD1 population_NN1 for_IF treatment_NN1 and_CC to_TO examine_VVI the_AT effectiveness_NN1 of_IO existing_JJ treatment_NN1 modalities_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   17 <p> L : BUPRENORPHINE/NALOXONE AS A NEW PHARMACOLOGICAL TREATMENT Buprenorphine/naloxone , is an evidence-based pharmacological treatment that offers a new and different option for treatment of opioid dependence .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   17 <p>_Y L_ZZ1_NP1@ :_Y BUPRENORPHINE/NALOXONE_VV0_NP1_NN1 AS_CSA_II A_ZZ1_AT1@ NEW_JJ PHARMACOLOGICAL_JJ TREATMENT_NN1 Buprenorphine/naloxone_NN1_VV0 ,_Y is_VBZ an_AT1 evidence-based_JJ pharmacological_JJ treatment_NN1 that_CST_DD1 offers_VVZ@ a_AT1 new_JJ and_CC different_JJ option_NN1 for_IF treatment_NN1 of_IO opioid_JJ_NN1 dependence_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   18 This medication blocks .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   18 This_DD1 medication_NN1 blocks_VVZ@_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   19 It has been demonstrated to be effective with heroin dependence ( Fiellin et al. , 2002 ; Ling et al. , 1998 ; Prescrire Editorial Staff , 2006 ) , and studies are now being conducted by the National Institute on Drug Abuse ( NIDA ) to demonstrate its effectiveness with those dependent on prescription pain medication ( see NIDA Clinical Trials Network at http : **41;3590;TOOLONG ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   19 It_PPH1 has_VHZ been_VBN demonstrated_VVN to_TO be_VBI effective_JJ with_IW heroin_NN1 dependence_NN1 (_Y Fiellin_NP1 et_RA21 al._RA22 ,_Y 2002_MC ;_Y Ling_NN1 et_RA21 al._RA22 ,_Y 1998_MC ;_Y Prescrire_VV0_NP1 Editorial_JJ_NN1 Staff_NN ,_Y 2006_MC )_Y ,_Y and_CC studies_NN2 are_VBR now_RT being_VBG conducted_VVN by_II the_AT National_JJ Institute_NN1 on_II Drug_NN1 Abuse_NN1 (_Y NIDA_NP1 )_Y to_TO demonstrate_VVI its_Z' effectiveness_NN1 with_IW those_DD2 dependent_JJ on_II prescription_NN1 pain_NN1 medication_NN1 (_Y see_VV0 NIDA_NP1_NN1 Clinical_JJ Trials_NN2 Network_NN1 at_II http_NNU :_Y **41;3590;TOOLONG_FU )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   20 Beginning in October 2002 , physicians who take a sanctioned course can prescribe buprenorphine/naloxone as a sublingual tablet for opioid addiction from a private office rather than exclusively through specialized drug treatment centers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   20 Beginning_VVG_NN1 in_II October_NPM1 2002_MC ,_Y physicians_NN2 who_PNQS take_VV0 a_AT1 sanctioned_JJ@ course_NN1 can_VM prescribe_VVI buprenorphine/naloxone_NN1_VV0 as_II_CSA a_AT1 sublingual_JJ tablet_NN1 for_IF opioid_JJ_NN1 addiction_NN1 from_II a_AT1 private_JJ office_NN1 rather_II21_CS21@ than_II22_CS22@ exclusively_RR through_II specialized_JJ drug_NN1 treatment_NN1 centers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   21 This has increased accessibility to patients and decreased stigma associated with drug treatment .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   21 This_DD1 has_VHZ increased_VVN accessibility_NN1 to_II patients_NN2 and_CC decreased_JJ@_VVD_VVN stigma_NN1 associated_VVN with_IW drug_NN1 treatment_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   22 <p> Buprenorphine/naloxone has numerous clinical advantages .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   22 <p>_Y Buprenorphine/naloxone_NN1_VV0 has_VHZ numerous_JJ clinical_JJ advantages_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   23 Because of its unique makeup it can be used in two valuable ways : detoxification and stabilization or maintenance .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   23 Because_II21 of_II22 its_Z' unique_JJ makeup_NN1 it_PPH1 can_VM be_VBI used_VVN in_II two_MC valuable_JJ ways_NN2 :_Y detoxification_NN1 and_CC stabilization_NN1 or_CC maintenance_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   24 For detoxification , buprenorphine/naloxone allows for alleviation of withdrawal symptoms , even on an outpatient basis , while inhibiting further use and misuse of those drugs while on the medication .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   24 For_IF detoxification_NN1 ,_Y buprenorphine/naloxone_NN1 allows_VVZ for_IF alleviation_NN1 of_IO withdrawal_NN1 symptoms_NN2 ,_Y even_RR on_II an_AT1 outpatient_NN1 basis_NN1 ,_Y while_CS inhibiting_VVG further_JJR@_RRR use_NN1_VV0 and_CC misuse_NN1 of_IO those_DD2 drugs_NN2 while_CS_VV0% on_II the_AT medication_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   25 Physical functioning is restored quickly , freeing the person to direct energy and attention to a pharmacologically supported stabilization and maintenance period .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   25 Physical_JJ functioning_NN1@ is_VBZ restored_VVN quickly_RR ,_Y freeing_VVG the_AT person_NN1 to_TO direct_VVI energy_NN1 and_CC attention_NN1 to_II a_AT1 pharmacologically_RR supported_VVN_JJ@_VVD stabilization_NN1 and_CC maintenance_NN1 period_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   26 This intervention provides dependent individuals with an extended time in which they can accomplish necessary habit changes ( both cognitive and behavioral ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   26 This_DD1 intervention_NN1 provides_VVZ dependent_JJ individuals_NN2 with_IW an_AT1 extended_JJ@ time_NNT1 in_II which_DDQ they_PPHS2 can_VM accomplish_VVI necessary_JJ habit_NN1 changes_NN2 (_Y both_DB2_RR cognitive_JJ and_CC behavioral_NN1_JJ )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   27 Abstinence is supported because the medication interrupts and inhibits the effect of opioids in the brain .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   27 Abstinence_NN1 is_VBZ supported_VVN because_CS the_AT medication_NN1 interrupts_NN2 and_CC inhibits_VVZ the_AT effect_NN1 of_IO opioids_NN2 in_II the_AT brain_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   28 <p> Buprenorphine/naloxone is effective because it relieves withdrawal symptoms , does not make the person feel high , interferes with the use of other opioids , and is very difficult to misuse .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   28 <p>_Y Buprenorphine/naloxone_NN1_VV0 is_VBZ effective_JJ because_CS it_PPH1 relieves_VVZ withdrawal_NN1 symptoms_NN2 ,_Y does_VDZ not_XX make_VVI the_AT person_NN1 feel_VVI high_JJ_RR@ ,_Y interferes_VVZ with_IW the_AT use_NN1 of_IO other_JJ opioids_NN2 ,_Y and_CC is_VBZ very_RG difficult_JJ to_TO misuse_VVI ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   29 It is the physical withdrawal symptoms in opioid addicts that significantly interfere with discontinuing use of the drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   29 It_PPH1 is_VBZ the_AT physical_JJ withdrawal_NN1 symptoms_NN2 in_II opioid_JJ_NN1 addicts_NN2 that_CST significantly_RR interfere_VV0 with_IW discontinuing_VVG_JJ@ use_NN1 of_IO the_AT drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   30 Because buprenorphine/naloxone is a mild agonist , a substance abuser does not need to be fully detoxified to receive the medication .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   30 Because_CS buprenorphine/naloxone_NN1 is_VBZ a_AT1 mild_JJ agonist_NN1 ,_Y a_AT1 substance_NN1 abuser_NN1 does_VDZ not_XX need_VVI to_TO be_VBI fully_RR detoxified_VVN to_TO receive_VVI the_AT medication_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   31 <p> Buprenorphine/naloxone is safer and less prone to abuse than are other opioids , including methadone , because of its ceiling effect .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   31 <p>_Y Buprenorphine/naloxone_NN1_VV0 is_VBZ safer_JJR and_CC less_RGR prone_JJ to_TO abuse_VVI than_CSN are_VBR other_JJ opioids_NN2 ,_Y including_II_VVG@ methadone_NN1 ,_Y because_II21 of_II22 its_Z' ceiling_NN1 effect_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   32 Taking more of it does not make a person " higher , " and it is safer because there is no increasing effect on respiratory depression , which is often the cause of overdose ( Bowersox , 1995 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   32 Taking_VVG more_DAR of_IO it_PPH1 does_VDZ not_XX make_VVI a_AT1 person_NN1 "_Y higher_RRR@_JJR ,_Y "_Y and_CC it_PPH1 is_VBZ safer_JJR_RRR because_CS there_EX is_VBZ no_AT increasing_JJ effect_NN1 on_II respiratory_JJ depression_NN1 ,_Y which_DDQ is_VBZ often_RR the_AT cause_NN1 of_IO overdose_NN1 (_Y Bowersox_NP1_NN1 ,_Y 1995_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   33 Furthermore , it is less a heightened effect by doubling up with other opioids .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   33 Furthermore_RR ,_Y it_PPH1 is_VBZ less_RGR a_AT1 heightened_JJ effect_NN1 by_II doubling_VVG up_RP with_IW other_JJ opioids_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   34 Buprenorphine/naloxone blocks the effects of other opioids , which means that if an individual uses a drug such as oxycodone or heroin while taking the medication , there is no effect from that drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   34 Buprenorphine/naloxone_NN1_VV0 blocks_VVZ@_NN2 the_AT effects_NN2 of_IO other_JJ opioids_NN2 ,_Y which_DDQ means_VVZ that_CST if_CS an_AT1 individual_NN1_JJ uses_VVZ a_AT1 drug_NN1 such_II21 as_II22 oxycodone_NN1 or_CC heroin_NN1 while_CS taking_VVG the_AT medication_NN1 ,_Y there_EX is_VBZ no_AT effect_NN1 from_II that_DD1 drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   35 In addition , this medication has a built-in mechanism that discourages misuse through crushing , snorting , or injecting .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   35 In_RR21 addition_RR22 ,_Y this_DD1 medication_NN1 has_VHZ a_AT1 built-in_JJ mechanism_NN1 that_CST_DD1 discourages_VVZ misuse_NN1 through_II crushing_VVG_JJ ,_Y snorting_VVG ,_Y or_CC injecting_VVG ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   36 If used in any of these ways , the effects of buprenorphine are not felt and the naloxone ( which has no clinical effect when taken sublingually as prescribed ) is felt in full force , causing the individual to go into immediate withdrawal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   36 If_CS used_VVN in_II any_DD of_IO these_DD2 ways_NN2 ,_Y the_AT effects_NN2 of_IO buprenorphine_NN1 are_VBR not_XX felt_VVN and_CC the_AT naloxone_NN1 (_Y which_DDQ has_VHZ no_AT clinical_JJ effect_NN1 when_CS_RRQ taken_VVN sublingually_RR as_CSA_RG@ prescribed_VVN_JJ )_Y is_VBZ felt_VVN in_II_RR21 full_JJ_RR22 force_NN1_VV0@ ,_Y causing_VVG the_AT individual_JJ_NN1 to_TO go_VVI into_II immediate_JJ withdrawal_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   37 <p> L : CLINICAL TREATMENT With the growing trend of dependence on prescription pain medications and the increase in use of pharmacological treatments of addictions , new treatment models are needed to address and support long-term recovery .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   37 <p>_Y L_ZZ1_NP1@ :_Y CLINICAL_JJ TREATMENT_NN1 With_IW the_AT growing_JJ trend_NN1 of_IO dependence_NN1 on_II prescription_NN1 pain_NN1 medications_NN2 and_CC the_AT increase_NN1 in_II use_NN1 of_IO pharmacological_JJ treatments_NN2 of_IO addictions_NN2 ,_Y new_JJ treatment_NN1 models_NN2 are_VBR needed_VVN to_TO address_VVI and_CC support_VVI long-term_JJ recovery_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   38 At the West Virginia University Department of Behavioral Medicine , a model for treatment of opioid dependence that uses a combination of two evidence-based treatments is being offered to opioid-dependent clients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   38 At_II the_AT West_NP1 Virginia_NP1 University_NN1 Department_NN1 of_IO Behavioral_JJ_NP1_NN1 Medicine_NN1 ,_Y a_AT1 model_NN1 for_IF treatment_NN1 of_IO opioid_JJ_NN1 dependence_NN1 that_CST_DD1 uses_VVZ a_AT1 combination_NN1 of_IO two_MC evidence-based_JJ treatments_NN2 is_VBZ being_VBG offered_VVN to_II opioid-dependent_JJ clients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   39 The majority of these clients are dependent on prescription pain pills includes treatment with buprenorphine/ naloxone and 12-step facilitation therapy ( Nowinski , Baker , Carroll , 1994 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   39 The_AT majority_NN1 of_IO these_DD2 clients_NN2 are_VBR dependent_JJ on_II prescription_NN1 pain_NN1 pills_NN2 includes_VVZ treatment_NN1 with_IW buprenorphine/_NN1 naloxone_NN1 and_CC 12-step_JJ_NN1 facilitation_NN1 therapy_NN1 (_Y Nowinski_NP1_NN1 ,_Y Baker_NP1 ,_Y Carroll_NP1 ,_Y 1994_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   40 During the first half hour of a weekly 90-minute group , clients see the physician , report on required 12-step meeting attendance , complete random drug screens , and receive education about the medication .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   40 During_II the_AT first_MD half_DB_NN1@ hour_NNT1 of_IO a_AT1 weekly_JJ 90-minute_JJ group_NN1 ,_Y clients_NN2 see_VV0 the_AT physician_NN1 ,_Y report_NN1_VV0@ on_II required_JJ 12-step_JJ_NN1 meeting_NN1_VVG attendance_NN1 ,_Y complete_JJ_VV0 random_JJ drug_NN1 screens_NN2 ,_Y and_CC receive_VV0 education_NN1 about_II the_AT medication_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   41 During the subsequent 60 minutes they engage in a group that teaches about concepts important to 12-step participation .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   41 During_II the_AT subsequent_JJ 60_MC minutes_NNT2 they_PPHS2 engage_VV0 in_II_RP@ a_AT1 group_NN1 that_CST_DD1 teaches_VVZ about_II_RP@ concepts_NN2 important_JJ to_II 12-step_JJ_NN1 participation_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   42 Objectives of 12-step facilitation therapy include identifying and changing cognitions related to drug use , learning to deal with emotional states that contribute to use , developing behaviors that support abstinence , increasing healthy social and relational supports , and taking part in activities that enhance hope and trust .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   42 Objectives_NN2 of_IO 12-step_JJ_NN1 facilitation_NN1 therapy_NN1 include_VV0 identifying_VVG_JJ@ and_CC changing_JJ_VVG cognitions_NN2 related_VVN_VVD to_II drug_NN1 use_NN1_VV0 ,_Y learning_VVG to_TO deal_VVI with_IW emotional_JJ states_NN2 that_CST contribute_VV0 to_TO use_VVI ,_Y developing_VVG_JJ behaviors_NN2 that_CST_DD1 support_VV0_NN1 abstinence_NN1 ,_Y increasing_VVG_JJ healthy_JJ social_JJ and_CC relational_JJ supports_NN2 ,_Y and_CC taking_VVG part_NN1 in_II activities_NN2 that_CST enhance_VV0 hope_NN1_VV0 and_CC trust_NN1_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   43 Journaling is encouraged as a way of increasing engagement and self-reflection .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   43 Journaling_NP1@_VVG_NN1@ is_VBZ encouraged_VVN as_II a_AT1 way_NN1 of_IO increasing_JJ_VVG engagement_NN1 and_CC self-reflection_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   44 This 60-minute segment ends with a commitment from group members regarding their recovery activities for the week .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   44 This_DD1 60-minute_JJ segment_NN1 ends_VVZ_NN2 with_IW a_AT1 commitment_NN1 from_II group_NN1 members_NN2 regarding_II_VVG their_APPGE recovery_NN1 activities_NN2 for_IF the_AT week_NNT1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   45 Clients participate in the weekly group until they have 90 days of abstinence and a sponsor .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   45 Clients_NN2 participate_VV0 in_II_RP@ the_AT weekly_JJ group_NN1 until_CS they_PPHS2 have_VH0 90_MC days_NNT2 of_IO abstinence_NN1 and_CC a_AT1 sponsor_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   46 At that time they are referred to a monthly group that consists of meeting with the physician , reporting on treatment planning addresses issues such as length of treatment and other specialized needs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   46 At_II that_DD1 time_NNT1 they_PPHS2 are_VBR referred_VVN to_II a_AT1 monthly_JJ group_NN1 that_CST_DD1 consists_VVZ of_IO meeting_VVG_NN1 with_IW the_AT physician_NN1 ,_Y reporting_VVG on_II_RP@ treatment_NN1 planning_NN1_VVG addresses_VVZ_NN2 issues_NN2 such_II21 as_II22 length_NN1 of_IO treatment_NN1 and_CC other_JJ specialized_JJ needs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   47 <p> L : IMPLICATIONS FOR PRACTICE For social workers addressing the problem of prescription pain pill dependence , there are four primary areas of intervention : treatment , education , advocacy , and research .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   47 <p>_Y L_ZZ1_NP1@ :_Y IMPLICATIONS_NN2 FOR_IF PRACTICE_NN1 For_IF social_JJ workers_NN2 addressing_VVG the_AT problem_NN1 of_IO prescription_NN1 pain_NN1 pill_NN1 dependence_NN1 ,_Y there_EX are_VBR four_MC primary_JJ areas_NN2 of_IO intervention_NN1 :_Y treatment_NN1 ,_Y education_NN1 ,_Y advocacy_NN1 ,_Y and_CC research_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   48 Treatment should be provided through a multidisciplinary , abstinence-based approach , with physicians and social workers collaborating by using evidence-based treatments such as those described earlier .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   48 Treatment_NN1 should_VM be_VBI provided_VVN through_II a_AT1 multidisciplinary_NN1_JJ ,_Y abstinence-based_JJ_NN1 approach_NN1 ,_Y with_IW physicians_NN2 and_CC social_JJ workers_NN2 collaborating_VVG by_II using_VVG evidence-based_JJ_NN1 treatments_NN2 such_II21 as_II22 those_DD2 described_VVN_VVD earlier_RRR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   49 <p> Education is essential to refer or provide effective treatment to this population .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   49 <p>_Y Education_NN1 is_VBZ essential_JJ to_TO refer_VVI or_CC provide_VVI effective_JJ treatment_NN1 to_II this_DD1 population_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   50 Social workers need to be knowledgeable about the increase in the dependence on prescription pain pills and about the role that buprenorphine/naloxone can play in the recovery process , including its strengths and limitations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   50 Social_JJ workers_NN2 need_VV0 to_TO be_VBI knowledgeable_JJ about_II the_AT increase_NN1 in_II the_AT dependence_NN1 on_II prescription_NN1 pain_NN1 pills_NN2 and_CC about_II the_AT role_NN1 that_CST_DD1 buprenorphine/naloxone_NN1_VV0 can_VM play_VVI in_II the_AT recovery_NN1 process_NN1_VV0 ,_Y including_II_VVG@ its_Z' strengths_NN2 and_CC limitations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   51 The goal of buprenorphine/naloxone therapy in the treatment of opioid addiction is to prevent withdrawal symptoms and to suppress cravings for opioids .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   51 The_AT goal_NN1 of_IO buprenorphine/naloxone_NN1 therapy_NN1 in_II the_AT treatment_NN1 of_IO opioid_JJ_NN1 addiction_NN1 is_VBZ to_TO prevent_VVI withdrawal_NN1 symptoms_NN2 and_CC to_TO suppress_VVI cravings_NN2 for_IF opioids_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   52 The medication , however , does not treat addictive patterns and behaviors .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   52 The_AT medication_NN1 ,_Y however_RR ,_Y does_VDZ not_XX treat_VVI addictive_JJ patterns_NN2 and_CC behaviors_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   53 It gives the addicted person the support to stop using drugs , but it does not provide social support systems or alternate patterns of behavior and cognitions that are needed individual can just stop using the drug the problem will be solved .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   53 It_PPH1 gives_VVZ the_AT addicted_JJ@ person_NN1 the_AT support_NN1 to_TO stop_VVI using_VVG drugs_NN2 ,_Y but_CCB it_PPH1 does_VDZ not_XX provide_VVI social_JJ support_NN1 systems_NN2 or_CC alternate_JJ_VV0 patterns_NN2 of_IO behavior_NN1 and_CC cognitions_NN2 that_CST are_VBR needed_VVN individual_NN1 can_VM just_RR stop_VVI using_VVG the_AT drug_NN1 the_AT problem_NN1 will_VM be_VBI solved_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   54 To the nave user and her or his family , the social systems , and even the prescribing clinician , buprenorphine/naloxone may give the illusion of " fixing " the problem by simply helping an individual to stop using opioids .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   54 To_II the_AT nave_NN1 user_NN1 and_CC her_PPHO1_APPGE or_CC his_APPGE family_NN1 ,_Y the_AT social_JJ systems_NN2 ,_Y and_CC even_RR the_AT prescribing_NN1@ clinician_NN1 ,_Y buprenorphine/naloxone_NN1_VV0 may_VM give_VVI the_AT illusion_NN1 of_IO "_Y fixing_VVG "_Y the_AT problem_NN1 by_II simply_RR helping_VVG an_AT1 individual_JJ_NN1 to_TO stop_VVI using_VVG opioids_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   55 All can be seduced into believing that once the drug is out of a person 's system the individual no longer suffers the negative effects of drug addiction .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   55 All_DB_RR@ can_VM be_VBI seduced_VVN into_II believing_VVG that_CST_DD1 once_CS@_RR the_AT drug_NN1 is_VBZ out_II21 of_II22 a_AT1 person_NN1 's_GE system_NN1 the_AT individual_NN1_JJ no_RR21 longer_RR22 suffers_VVZ the_AT negative_JJ effects_NN2 of_IO drug_NN1 addiction_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   56 <p> Advocacy is needed to ensure the effective use of this medication and to inhibit its misuse .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   56 <p>_Y Advocacy_NN1 is_VBZ needed_VVN to_TO ensure_VVI the_AT effective_JJ use_NN1 of_IO this_DD1 medication_NN1 and_CC to_TO inhibit_VVI its_Z' misuse_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   57 Because it is less strictly regulated than methadone , buprenorphine/naloxone has an initial advantage of availability .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   57 Because_CS it_PPH1 is_VBZ less_RGR strictly_RR regulated_VVN_JJ@ than_CSN methadone_NN1_VV0 ,_Y buprenorphine/naloxone_NN1_VV0 has_VHZ an_AT1 initial_JJ_NN1 advantage_NN1 of_IO availability_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   58 However , this availability has its downside .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   58 However_RR ,_Y this_DD1 availability_NN1 has_VHZ its_Z' downside_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   59 Without the necessary support and education , clients are at risk of not receiving needed therapy and emphasis on life changes .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   59 Without_IW the_AT necessary_JJ support_NN1 and_CC education_NN1 ,_Y clients_NN2 are_VBR at_II risk_NN1 of_IO not_XX receiving_VVG needed_VVN_VVD therapy_NN1 and_CC emphasis_NN1 on_II life_NN1 changes_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   60 A combined medical management and abstinence-based therapeutic approach offers both the physiological support for detoxification and maintenance and the support for lifestyle changes necessary for enduring recovery .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   60 A_AT1_ZZ1 combined_JJ medical_JJ management_NN1 and_CC abstinence-based_JJ therapeutic_JJ approach_NN1 offers_NN2_VVZ@ both_RR_DB2 the_AT physiological_JJ support_NN1 for_IF detoxification_NN1 and_CC maintenance_NN1 and_CC the_AT support_NN1 for_IF lifestyle_NN1 changes_VVZ@_NN2 necessary_JJ for_IF enduring_JJ_VVG recovery_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   61 Long-term relief from drug addiction can be achieved by treating the withdrawal symptoms and supporting emotional responses , and family and social systems that support long-term recovery .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   61 Long-term_JJ relief_NN1 from_II drug_NN1 addiction_NN1 can_VM be_VBI achieved_VVN by_II treating_VVG the_AT withdrawal_NN1 symptoms_NN2 and_CC supporting_VVG emotional_JJ responses_NN2 ,_Y and_CC family_NN1 and_CC social_JJ systems_NN2 that_CST support_VV0 long-term_JJ recovery_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   62 <p> Another disadvantage of less strict regulation of buprenorphine/naloxone is the increase in its street availability .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   62 <p>_Y Another_DD1 disadvantage_NN1 of_IO less_RGR strict_JJ regulation_NN1 of_IO buprenorphine/naloxone_NN1 is_VBZ the_AT increase_NN1 in_II its_Z' street_NN1 availability_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   63 Although the drug has some inherent safety mechanisms , it still can be bartered and sold for other drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   63 Although_CS the_AT drug_NN1 has_VHZ some_DD inherent_JJ safety_NN1 mechanisms_NN2 ,_Y it_PPH1 still_RR can_VM be_VBI bartered_VVN_JJ and_CC sold_VVN_VVD for_IF other_JJ drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   64 This medication can be misused in a way that supports ongoing addiction to other drugs of abuse .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   64 This_DD1 medication_NN1 can_VM be_VBI misused_VVN in_II a_AT1 way_NN1 that_CST_DD1 supports_VVZ ongoing_JJ addiction_NN1 to_II other_JJ drugs_NN2 of_IO abuse_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   65 For example , an individual may use buprenorphine/naloxone to prevent withdrawal during a time that he or she can not find or afford the drug of choice , only to return to the use of that drug when it becomes available .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   65 For_REX21 example_REX22 ,_Y an_AT1 individual_NN1 may_VM use_VVI buprenorphine/naloxone_NN1_VV0 to_TO prevent_VVI withdrawal_NN1 during_II a_AT1 time_NNT1 that_CST he_PPHS1 or_CC she_PPHS1 can_VM not_XX find_VVI or_CC afford_VVI the_AT drug_NN1 of_IO choice_NN1 ,_Y only_RR to_II return_NN1 to_II the_AT use_NN1 of_IO that_DD1 drug_NN1 when_CS_RRQ it_PPH1 becomes_VVZ available_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   66 It can also be used during the week , with the plan to return to " partying " on the weekend .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   66 It_PPH1 can_VM also_RR be_VBI used_VVN during_II the_AT week_NNT1 ,_Y with_IW the_AT plan_NN1 to_TO return_VVI to_II "_Y partying_VVG "_Y on_II the_AT weekend_NNT1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   67 <p> Research is needed to increase social workers ' understanding of the successful tools and protocols that are effective for the treatment of prescription drug abuse .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   67 <p>_Y Research_NN1 is_VBZ needed_VVN to_TO increase_VVI social_JJ workers_NN2 '_GE understanding_NN1 of_IO the_AT successful_JJ tools_NN2 and_CC protocols_NN2 that_CST are_VBR effective_JJ for_IF the_AT treatment_NN1 of_IO prescription_NN1 drug_NN1 abuse_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   68 For example , research could promote understanding of what doses of buprenorphine/ naloxone are most effective on the basis of a person 's level of tolerance of opioids .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   68 For_REX21 example_REX22 ,_Y research_NN1 could_VM promote_VVI understanding_NN1 of_IO what_DDQ doses_NN2 of_IO buprenorphine/_NN1 naloxone_NN1 are_VBR most_RGT effective_JJ on_II the_AT basis_NN1 of_IO a_AT1 person_NN1 's_GE level_NN1 of_IO tolerance_NN1 of_IO opioids_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   69 In addition , to best promote long-term abstinence would provide more clear treatment protocols .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   69 In_RR21 addition_RR22 ,_Y to_TO best_RRT_JJT promote_VVI long-term_JJ abstinence_NN1 would_VM provide_VVI more_RGR_DAR clear_JJ treatment_NN1 protocols_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   70 <p> Buprenorphine/naloxone is an exciting new tool and , as is characteristic of all tools , it is used best with an understanding of its limitations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   70 <p>_Y Buprenorphine/naloxone_NN1_VV0 is_VBZ an_AT1 exciting_JJ new_JJ tool_NN1 and_CC ,_Y as_CSA is_VBZ characteristic_JJ_NN1 of_IO all_DB tools_NN2 ,_Y it_PPH1 is_VBZ used_VVN_JJ best_VV0% with_IW an_AT1 understanding_NN1 of_IO its_Z' limitations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   71 Although at times history has shown failure of promise with new pharmacological interventions , medications are showing an increasing role in the treatment of addiction to various drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   71 Although_CS at_II times_NNT2 history_NN1 has_VHZ shown_VVN failure_NN1 of_IO promise_NN1 with_IW new_JJ pharmacological_JJ interventions_NN2 ,_Y medications_NN2 are_VBR showing_VVG an_AT1 increasing_JJ role_NN1 in_II the_AT treatment_NN1 of_IO addiction_NN1 to_II various_JJ drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   72 Sometimes the failure of new promise is born out of misunderstanding of the best use of a new intervention .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   72 Sometimes_RT the_AT failure_NN1 of_IO new_JJ promise_NN1 is_VBZ born_VVN out_II21 of_II22 misunderstanding_NN1 of_IO the_AT best_JJT use_NN1 of_IO a_AT1 new_JJ intervention_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   73 Buprenorphine/naloxone can be used for both detoxification and maintenance , but it does not do the hard work of cognition and habit change that is so important for overall success in the treatment of drug addiction .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   73 Buprenorphine/naloxone_NN1_VV0 can_VM be_VBI used_VVN for_IF both_RR detoxification_NN1 and_CC maintenance_NN1 ,_Y but_CCB it_PPH1 does_VDZ not_XX do_VDI the_AT hard_JJ work_NN1 of_IO cognition_NN1 and_CC habit_NN1 change_VV0_NN1 that_DD1_CST is_VBZ so_RG_RR important_JJ for_IF overall_JJ_NN1 success_NN1 in_II the_AT treatment_NN1 of_IO drug_NN1 addiction_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   74 <p> Drug dependence is accompanied by habits that must be changed to support long-term health .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   74 <p>_Y Drug_NN1 dependence_NN1 is_VBZ accompanied_VVN by_II habits_NN2 that_CST_DD1 must_VM be_VBI changed_VVN to_TO support_VVI long-term_JJ health_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   75 Through an understanding of the changing trends in drugs of abuse and the strengths and limitations of new evidence-based treatments , social workers can support the use of these interventions in a way that is most advantageous to their clients and society .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   75 Through_II an_AT1 understanding_NN1 of_IO the_AT changing_JJ trends_NN2 in_II drugs_NN2 of_IO abuse_NN1 and_CC the_AT strengths_NN2 and_CC limitations_NN2 of_IO new_JJ evidence-based_JJ_NN1 treatments_NN2 ,_Y social_JJ workers_NN2 can_VM support_VVI the_AT use_NN1 of_IO these_DD2 interventions_NN2 in_II a_AT1 way_NN1 that_CST_DD1 is_VBZ most_RGT advantageous_JJ to_II their_APPGE clients_NN2 and_CC society_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   76 Identification of addiction in vulnerable populations and for the treatment of this destructive disease and pervasive societal problem .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   76 Identification_NN1 of_IO addiction_NN1 in_II vulnerable_JJ populations_NN2 and_CC for_IF the_AT treatment_NN1 of_IO this_DD1 destructive_JJ disease_NN1 and_CC pervasive_JJ societal_JJ problem_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   77 <p> L : REFERENCES -- Bowersox , J. ( 1995 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   77 <p>_Y L_ZZ1_NP1@ :_Y REFERENCES_NN2_VVZ@ --_ZZ Bowersox_NN1_NP1 ,_Y J._NP1 (_Y 1995_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   78 Buprenorphine/naloxone may soon be heroin treatment option .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   78 Buprenorphine/naloxone_NN1_VV0 may_VM soon_RR be_VBI heroin_NN1 treatment_NN1 option_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   79 NIDA Notes , 10(1) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   79 NIDA_NP1_NN1 Notes_NN2_VVZ@ ,_Y 10(1)_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   80 Retrieved November 10 , 2007 , from http : **53;3633;TOOLONG <p> -- Center for Substance Abuse Research .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   80 Retrieved_VVN_JJ@_VVD November_NPM1 10_MC ,_Y 2007_MC ,_Y from_II http_NNU :_Y **53;3633;TOOLONG_FU <p>_Y --_ZZ Center_NN1 for_IF Substance_NN1 Abuse_NN1 Research_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   81 ( 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   81 (_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   82 National treatment admissions for primary abuse of heroin decrease : Other opiates and methamphetamine increase .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   82 National_JJ treatment_NN1 admissions_NN2 for_IF primary_JJ_NN1 abuse_NN1 of_IO heroin_NN1 decrease_NN1_VV0 :_Y Other_JJ opiates_NN2 and_CC methamphetamine_VV0_NN1 increase_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   83 Retrieved March 20 , 2007 , from **48;3688;TOOLONG <p> -- Fiellin , D.A. , Pantalon , M.V. , Pakes , U. P. , O'Connor , E G. , Chawarski , M. , Schottenfeld , R. S. ( 2002 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   83 Retrieved_VVN_JJ@_VVD March_NPM1 20_MC ,_Y 2007_MC ,_Y from_II **48;3688;TOOLONG_NNU <p>_Y --_ZZ Fiellin_NP1_NN1@ ,_Y D.A._NP1 ,_Y Pantalon_NP1_NN1 ,_Y M.V._NNB ,_Y Pakes_NP2_NN2@_VVZ@ ,_Y U._NP1 P._NP1 ,_Y O'Connor_NP1 ,_Y E_ZZ1_NP1@ G._NP1_NNU@ ,_Y Chawarski_NP1_NN1 ,_Y M._NN1 ,_Y Schottenfeld_NP1_VV0_NN1 ,_Y R._NP1 S._NP1 (_Y 2002_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   84 Treatment of heroin dependence with buprenorphine in primary care .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   84 Treatment_NN1 of_IO heroin_NN1 dependence_NN1 with_IW buprenorphine_NN1 in_II primary_JJ_NN1 care_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   85 American Journal of Drug and Alcohol Abuse , 28(2) , 231-241 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   85 American_JJ Journal_NN1 of_IO Drug_NN1 and_CC Alcohol_NN1 Abuse_NN1 ,_Y 28(2)_FO ,_Y 231-241_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   86 <p> -- Ling , W , Charuvastra , C. , Collins , J. F. , Batki , S. , Brown , L. S. , Kintaudi , P. , Wesson , D. R. , McNicholas , L. , Tusel , D.J. , Malkerneker , U. , Renner , J.A. , Jr. , Santos , , Stine , S. , Wang , Wang , Segal , D. ( 1998 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   86 <p>_Y --_ZZ Ling_NN1 ,_Y W_ZZ1 ,_Y Charuvastra_NP1 ,_Y C._NP1_ZZ1@ ,_Y Collins_NP1 ,_Y J._NP1 F._NP1 ,_Y Batki_NP1_NN1 ,_Y S._NP1 ,_Y Brown_NP1 ,_Y L._NP1 S._NP1 ,_Y Kintaudi_NP1 ,_Y P._NP1 ,_Y Wesson_NP1 ,_Y D._NP1 R._NP1 ,_Y McNicholas_NP1 ,_Y L._NP1 ,_Y Tusel_NP1 ,_Y D.J._NP1 ,_Y Malkerneker_NP1_NN1 ,_Y U._NP1 ,_Y Renner_NP1_NN1 ,_Y J.A._NP1 ,_Y Jr._NP1 ,_Y Santos_NP1 ,_Y ,_Y Stine_NP1 ,_Y S._NP1 ,_Y Wang_NP1 ,_Y Wang_NP1 ,_Y Segal_NP1 ,_Y D._NP1 (_Y 1998_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   87 Buprenorphine maintenance treatment of opiate dependence : A multicenter randomized clinical trial .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   87 Buprenorphine_VV0_NN1 maintenance_NN1 treatment_NN1 of_IO opiate_NN1 dependence_NN1 :_Y A_AT1@_ZZ1 multicenter_JJR_VV0 randomized_JJ@_VVD clinical_JJ trial_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   88 Addiction , 93 , 475-486 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   88 Addiction_NPX ,_Y 93_MC ,_Y 475-486_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   89 <p> -- Maxwell , J. C. ( 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   89 <p>_Y --_ZZ Maxwell_NP1 ,_Y J._NP1 C._NP1 (_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   90 Trends in the abuse of prescription drags .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   90 Trends_NN2 in_II the_AT abuse_NN1 of_IO prescription_NN1 drags_VVZ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   91 Austin , TX : Gulf Coast Addiction Technology Transfer Center ( GCATTC ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   91 Austin_NP1 ,_Y TX_NP1 :_Y Gulf_NP1 Coast_NN1 Addiction_NPX Technology_NN1 Transfer_NN1_VV0 Center_NN1 (_Y GCATTC_NP1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   92 Retrieved January 15 , 2007 , from www.utattc.net <p> -- National Survey on Drug Use and Health .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   92 Retrieved_VVN_JJ@_VVD January_NPM1 15_MC ,_Y 2007_MC ,_Y from_II www.utattc.net_NNU <p>_Y --_ZZ National_JJ Survey_NN1 on_II Drug_NN1 Use_NN1 and_CC Health_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   93 ( 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   93 (_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   94 Nomnedical users of pain relievers : Characteristics of recent initiates .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   94 Nomnedical_JJ users_NN2 of_IO pain_NN1 relievers_VVZ :_Y Characteristics_NN2 of_IO recent_JJ initiates_NN2%_VVZ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   95 Office of Applied Studies , Substance Abuse and Mental Health Administration ( SAMHSA ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   95 Office_NN1 of_IO Applied_JJ Studies_NN2 ,_Y Substance_NN1 Abuse_NN1 and_CC Mental_JJ Health_NN1 Administration_NN1 (_Y SAMHSA_NP1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   96 Retrieved January 15 , 2007 , from http : //www.oas.samhsa.gov <p> -- Nowinski , J. , Baker , S. , Carroll , K. M. ( 1994 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   96 Retrieved_VVN_JJ@_VVD January_NPM1 15_MC ,_Y 2007_MC ,_Y from_II http_NNU :_Y //www.oas.samhsa.gov_FU <p>_Y --_ZZ Nowinski_NN1_NP1_NN2@ ,_Y J._NP1 ,_Y Baker_NP1 ,_Y S._NP1 ,_Y Carroll_NP1 ,_Y K._NP1 M._NN1_NNU@ (_Y 1994_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   97 Twelve step facilitation therapy manual : A clinical research guide for therapists treating individuals with alcohol abuse and dependence ( NIH Publication No 94-3722 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   97 Twelve_MC step_NN1_VV0 facilitation_NN1 therapy_NN1 manual_NN1 :_Y A_ZZ1_AT1@ clinical_JJ research_NN1 guide_NN1_VV0 for_IF therapists_NN2 treating_VVG individuals_NN2 with_IW alcohol_NN1 abuse_NN1 and_CC dependence_NN1 (_Y NIH_NP1_NN1 Publication_NN1 No_XX 94-3722_MCMC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   98 Washington , DC : U.S. Department of Health and Human Services , National Institute on Alcohol Abuse and Alcoholism .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   98 Washington_NP1 ,_Y DC_NP1 :_Y U.S._NP1 Department_NN1 of_IO Health_NN1 and_CC Human_JJ_NN1 Services_NN2 ,_Y National_JJ Institute_NN1 on_II Alcohol_NN1 Abuse_NN1 and_CC Alcoholism_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0   99 Buprenorphine replacement therapy : A confirmed benefit .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0   99 Buprenorphine_VV0_NN1 replacement_NN1 therapy_NN1 :_Y A_ZZ1_AT1@ confirmed_JJ@ benefit_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0  100 Prescrire International , 15(82) , 64-70 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0  100 Prescrire_VV0 International_JJ ,_Y 15(82)_FO ,_Y 64-70_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0  101 <p> Original manuscript received March 15 , 2007 <p> Final revision received November 16 , 2007 <p> Accepted January 30 , 2008 <p> By Marilyn H. Byrne ; Laura Lander and Martha Ferris <p> Marilyn H. Byrne , ACSW , is associate professor , and Laura Lander , MSW , and Martha Ferris , MSW , are staff therapists , Department of Behavioral Medicine Psychiatry , West Virginia University , 930 Chestnut Ridge Road , Morgantown , WV 26505 ; e-mail : mbyrne@hsc.wvu.edu .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0  101 <p>_Y Original_JJ manuscript_NN1 received_VVD_VVN March_NPM1 15_MC ,_Y 2007_MC <p>_Y Final_JJ_NN1 revision_NN1 received_VVD_VVN November_NPM1 16_MC ,_Y 2007_MC <p>_Y Accepted_JJ_VVN January_NPM1 30_MC ,_Y 2008_MC <p>_Y By_II Marilyn_NP1 H._NP1 Byrne_NP1 ;_Y Laura_NP1 Lander_NN1 and_CC Martha_NP1 Ferris_NP1 <p>_Y Marilyn_NP1 H._NP1 Byrne_NP1 ,_Y ACSW_NP1_VV0_NN1 ,_Y is_VBZ associate_JJ professor_NN1 ,_Y and_CC Laura_NP1 Lander_NN1 ,_Y MSW_NP1 ,_Y and_CC Martha_NP1 Ferris_NP1 ,_Y MSW_NP1 ,_Y are_VBR staff_NN therapists_NN2 ,_Y Department_NN1 of_IO Behavioral_JJ_NP1_NN1 Medicine_NN1 Psychiatry_NN1_NP1 ,_Y West_NP1 Virginia_NP1 University_NN1 ,_Y 930_MC Chestnut_NP1 Ridge_NP1 Road_NNL1 ,_Y Morgantown_NP1 ,_Y WV_NP1 26505_MC ;_Y e-mail_NN1_VV0@ :_Y mbyrne@hsc.wvu.edu_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  A    0  102 <p>
SENTPOS COCA_acad_wlp_2009_04_FILE##4071488 COCA  B    0  102 <p>_Y
